Johnson & Johnson Medical Products (a division of Johnson & Johnson Inc). Credit: Raysonho at Open Grid Scheduler / Grid Engine.

Johnson and Johnson ( J&J) Medical Devices Companies, through its division Apsis, has acquired French surgical technologies developer Orthotaxy for an undisclosed amount.

The deal includes a robotic-assisted surgery solution currently being developed by Orthotaxy for both total and partial knee replacement.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

J&J intends to advance this solution as a cost-effective, time-efficient and easy-to-use option for a wide variety of orthopaedic surgery procedures and care settings.

The firm will primarily devise its complete orthopaedic solution based on the Orthotaxy’s technology. The new solution will be designed to leverage enabling technologies to personalise and optimise surgical procedures.

J&J’s orthopaedics unit DePuy Synthes group chairman Ciro Rӧmer said: “Our goal is to bring to market a robotic-assisted surgery technology that is an integral part of a comprehensive orthopaedics platform, delivering value to patients, physicians and healthcare providers across the episode of care.

“The new solution will be designed to leverage enabling technologies to personalise and optimise surgical procedures.”

“The team at Orthotaxy has significant expertise and passion in developing this platform, and we aspire to bring to market a differentiated technology that helps improve clinical outcomes and increases patient satisfaction.”

J&J believes that the latest deal is in line with its goal to develop a comprehensive digital surgery platform for better patient outcomes and standard of care.

The firm plans to further develop digital technology solutions that will deliver transformative care.

In addition to products for general surgery, J&J’s medical device portfolio includes orthopaedic and cardiovascular disease solutions.